Raia DrogasilBSP:RADL3 +0.70%91 FCF Margin % is 4.82% as of Mar. 2026, which is 1076% above its 10-year median of 0.41. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$29.94 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Raia Drogasil ranks worse than 57.1% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Raia Drogasil's Free Cash Flow for the
three
months ended in Mar. 2026 was R$510 Mil. Raia Drogasil's Revenue for the
three
months ended in Mar. 2026 was R$10,569 Mil. Therefore, Raia Drogasil's FCF Margin % for the quarter that ended in Mar. 2026 was 4.82%.
The historical rank and industry rank for Raia Drogasil's FCF Margin % or its related term are showing as below:
BSP:RADL3'
s FCF Margin % Range Over the Past 10 Years
Min: -1.2 Med: 0.41 Max: 3.99
Current: 0.82
During the past 13 years, the highest FCF Margin % of Raia Drogasil was 3.99%. The lowest was -1.20%. And the median was 0.41%.
BSP:RADL3's FCF Margin % is ranked worse than 57.1% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 3.39
vs BSP:RADL3: 0.82
Raia Drogasil FCF Margin % Related Terms
Raia Drogasil FCF Margin % Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a FCF Margin % of 4.82% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Raia Drogasil and its competitors. This is 1076% above median its historical median of 0.41. According to the industry distribution chart, Raia Drogasil ranks #382 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 57.1%.
Is Raia Drogasil's FCF Margin % too high?
Raia Drogasil's current FCF Margin % of 4.82% is 1076% above median its 10-year median of 0.41. The Healthcare Providers & Services industry median FCF Margin % is 3.39. Raia Drogasil's value of 4.82% is 42.2% above this industry median. Based on the distribution chart, Raia Drogasil ranks #382 out of 669 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's FCF Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #382 out of 669 companies for FCF Margin %. This places Raia Drogasil in the lower half of its industry. The industry median FCF Margin % is 3.39. Raia Drogasil's value of 4.82% is 42.2% above this benchmark. While the company's 10-year median is 0.41 vs. the industry median of 3.39, Raia Drogasil has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.39, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current FCF Margin % of 4.82% is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current FCF Margin % is 4.82%, which is 1076% above median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$29.94, compared to a current price of R$17.20 — trading 42.6% below its estimated fair value. The current FCF Margin % is 4.82%, which is 1076% above median its 10-year median of 0.41 and 42.2% above the Healthcare Providers & Services industry median of 3.39. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current FCF Margin % is 4.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$17.20 is trading 42.6% below its estimated GF Value™ of R$29.94.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
FCF Margin %: 4.82% (1076% above median its 10-year median of 0.41)
GF Value™: R$29.94 vs. price of R$17.20 (42.6% below fair value)
Industry Position: 42.2% above the Healthcare Providers & Services median (#382 of 669)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
